Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines (RVMD) will present new clinical data from its RAS(ON) inhibitor combination trials in pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026, July 1–4 in Munich.

Rhea-AI Summary

Revolution Medicines (RVMD) will present new clinical data from its RAS(ON) inhibitor combination trials in pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026, July 1–4 in Munich.

The program features two Phase 1/2 zoldonrasib combination orals and two Phase 3 RASolute trial posters in PDAC.

Argus Jun 25 session

+4.95% close to close Open Argus

Details

News Market Reaction – RVMD

In the Jun 25 session, RVMD gained 4.95%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands RVMD’s RAS(ON) program with combination and Phase 3 PDAC studies, reinforc...

Analysis

This announcement expands RVMD’s RAS(ON) program with combination and Phase 3 PDAC studies, reinforcing a deep pancreatic focus. Prior clinical catalysts have produced uneven stock responses, so upcoming ESMO data and any follow-on regulatory steps remain key watchpoints.

Key Figures

Congress dates: July 1–4, 2026 Company presentations: 4 presentations Oral session slot: 10 minutes +5 more

Congress dates

July 1–4, 2026

ESMO Gastrointestinal Cancers Congress 2026 in Munich

Company presentations

4 presentations

Oral and poster presentations on RAS(ON) pipeline at ESMO GI 2026

Oral session slot

10 minutes

Zoldonrasib + chemotherapy 1L mPDAC talk, July 2, 2:40–2:50 p.m. CEST

Oral session slot

10 minutes

Zoldonrasib + daraxonrasib 2L+ mPDAC talk, July 2, 2:50–3:00 p.m. CEST

Phase 3 trials

2 trials-in-progress

RASolute 303 and RASolute 304 Phase 3 PDAC studies

First-line setting

1L metastatic PDAC

Zoldonrasib plus chemotherapy Phase 1/2 trial population

Later-line setting

2L+ metastatic PDAC

Zoldonrasib plus daraxonrasib Phase 1/2 trial population

Adjuvant setting

Post-resection PDAC

RASolute 304 adjuvant daraxonrasib versus observation

Previous Clinical trial Reports

5 past events · Latest: Jun 23

Same Type 5 events

1. Jun 23

   Phase 3 trial start

   24h Move

   +2.2%

   Began treating patients in Phase 3 RASolute 305 in metastatic PDAC.

2. May 31

   Pivotal Phase 3 data

   24h Move

   +3.9%

   Reported RASolute 302 Phase 3 daraxonrasib data with strong survival benefit.

3. May 06

   Phase 1/2 publication

   24h Move

   -5.7%

   NEJM publication of daraxonrasib Phase 1/2 pancreatic cancer results supporting Phase 3.

4. Apr 21

   Phase 1/2 update

   24h Move

   -4.4%

   Updated Phase 1/2 daraxonrasib first-line mPDAC data at AACR 2026.

5. Apr 21

   Planned Phase 3 readout

   24h Move

   +1.8%

   Announced upcoming ASCO plenary for detailed RASolute 302 Phase 3 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pancreatic ductal adenocarcinoma, adjuvant, neoadjuvant, open-label, +2 more

6 terms

pancreatic ductal adenocarcinoma medical

"metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC)"

A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.

adjuvant medical

"adjuvant daraxonrasib in patients with PDAC who have undergone resection"

An adjuvant is an ingredient added to a vaccine or other therapy to strengthen or shape the body’s response to the main active component, like a helper that makes the primary ingredient work better or longer. For investors, adjuvants matter because they can change how well a product performs, alter dosing and safety profiles, affect regulatory review, and therefore influence clinical success, market size and competitive advantage.

neoadjuvant medical

"Following completion of neoadjuvant and/or adjuvant chemotherapy in patients"

"Neoadjuvant" describes treatments or interventions that are given before the main or primary procedure, such as surgery or a major decision. It’s like preparing the ground before planting seeds, aiming to improve the final outcome. For investors, understanding neoadjuvant approaches can provide insight into how companies enhance results or effectiveness in their processes or products.

open-label medical

"A Phase 3 Global, Multicenter, Open-Label, Randomized 3-Arm Study of"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

monotherapy medical

"daraxonrasib as a monotherapy or in combination with gemcitabine"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

randomized medical

"Phase 3 Multicenter, Open-label, Randomized Study of Adjuvant Daraxonrasib"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany.

The program will include two oral presentations from Phase 1/2 trials evaluating zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). These presentations will report results from zoldonrasib plus chemotherapy in the first line setting, and zoldonrasib plus daraxonrasib, the company’s oral RAS(ON) multi-selective inhibitor, in patients who had received one or more prior lines of therapy.

Additional presentations will include two Phase 3 trials-in-progress posters for RASolute 303, evaluating daraxonrasib as a monotherapy or in combination with gemcitabine and nab-paclitaxel versus standard of care gemcitabine and nab-paclitaxel as a first line treatment for patients with metastatic PDAC, and RASolute 304, evaluating adjuvant daraxonrasib in patients with PDAC who have undergone resection and completed perioperative chemotherapy.

Details of Revolution Medicines’ presentations are listed below.

Revolution Medicines Oral Presentations:

Title:	Safety and Efficacy of Zoldonrasib (RMC-9805) Plus Chemotherapy in Patients (pts) with 1L RAS G12D Metastatic Pancreatic Adenocarcinoma (mPDAC)
Abstract:	#340O
Presenter:	Brian Wolpin, M.D., Dana-Farber Cancer Institute
Session:	Proffered Paper Session
Date/Time:	July 2; 2:40 p.m. – 2:50 p.m. CEST

Title:	Safety and Efficacy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) in Patients with 2L+ KRAS G12D Metastatic Pancreatic Adenocarcinoma (mPDAC)
Abstract:	#341O
Presenter:	Nilofer Azad, M.D., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Session:	Proffered Paper Session
Date/Time:	July 2; 2:50 p.m. – 3:00 p.m. CEST

Revolution Medicines Posters:

Title:	RASolute 303: A Phase 3 Global, Multicenter, Open-Label, Randomized 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
Abstract:	#471TiP
Presenter:	Thomas Seufferlein, M.D., Ph.D., University Hospital Ulm
Session:	Upper Digestive – Biliary, ampullary and pancreatic cancer
Date/Time:	July 3; 3:30 p.m. – 4:30 p.m. CEST

Title:	RASolute 304 – A Phase 3 Multicenter, Open-label, Randomized Study of Adjuvant Daraxonrasib Versus Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma (PDAC)
Abstract:	#472TiP
Presenter:	Michel Ducreux, M.D., Ph.D., Institut Gustave Roussy
Session:	Upper Digestive – Biliary, ampullary and pancreatic cancer
Date/Time:	July 3; 3:30 p.m. – 4:30 p.m. CEST

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” "believe," "estimate," "expect," "plan," “potential,” “project,” “up to,” "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 6, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contact: 
media@revmed.com  
investors@revmed.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Revolution Medicines (RVMD) present at ESMO GI Cancers Congress 2026?

Revolution Medicines will present four RAS(ON) pipeline datasets in pancreatic cancer, including Phase 1/2 and Phase 3 trials. According to Revolution Medicines, these include zoldonrasib combination orals and RASolute 303/304 posters in metastatic and resected pancreatic ductal adenocarcinoma.

Which zoldonrasib pancreatic cancer trials from RVMD are featured at ESMO GI 2026?

Two Phase 1/2 zoldonrasib combination trials in metastatic RAS G12D pancreatic cancer will be featured. According to Revolution Medicines, one evaluates zoldonrasib plus chemotherapy first line, and one assesses zoldonrasib plus daraxonrasib in previously treated patients.

What is the focus of the RASolute 303 Phase 3 trial presented by RVMD?

RASolute 303 is a Phase 3 trial in first line metastatic pancreatic adenocarcinoma. According to Revolution Medicines, it compares daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel versus standard gemcitabine and nab-paclitaxel in a randomized, open-label, three-arm design.

What is the RASolute 304 Phase 3 trial Revolution Medicines will poster at ESMO 2026?

RASolute 304 is a Phase 3 adjuvant trial in resected pancreatic adenocarcinoma. According to Revolution Medicines, it randomizes patients to daraxonrasib versus observation after completing neoadjuvant and/or adjuvant chemotherapy, assessing outcomes following surgical resection.

When are Revolution Medicines’ oral presentations on zoldonrasib scheduled at ESMO GI 2026?

The zoldonrasib oral presentations are scheduled for July 2, 2026. According to Revolution Medicines, the chemotherapy combination talk runs 2:40–2:50 p.m. CEST, followed by the zoldonrasib plus daraxonrasib presentation from 2:50–3:00 p.m. CEST.

When will the RASolute 303 and 304 posters from RVMD be presented at ESMO GI 2026?

Both RASolute 303 and RASolute 304 posters are planned for July 3, 2026. According to Revolution Medicines, they will be shown in the Upper Digestive session from 3:30 p.m. to 4:30 p.m. CEST.